Clinical and genetic characterization of a cohort of 97 CLN6 patients tested at a single center.

Autor: Rus CM; Centogene GmbH, Am Strande 7, 18057, Rostock, Germany. corina-marcela.rus@uni-rostock.de.; Institute of Chemistry, University of Rostock, Dr.-Lorenz-Weg 2, 18059, Rostock, Germany. corina-marcela.rus@uni-rostock.de., Weissensteiner T; Centogene GmbH, Am Strande 7, 18057, Rostock, Germany., Pereira C; Centogene GmbH, Am Strande 7, 18057, Rostock, Germany., Susnea I; Centogene GmbH, Am Strande 7, 18057, Rostock, Germany., Danquah BD; Centogene GmbH, Am Strande 7, 18057, Rostock, Germany., Morales Torres G; Centogene GmbH, Am Strande 7, 18057, Rostock, Germany., Rocha ME; Centogene GmbH, Am Strande 7, 18057, Rostock, Germany., Cozma C; Centogene GmbH, Am Strande 7, 18057, Rostock, Germany., Saravanakumar D; Centogene GmbH, Am Strande 7, 18057, Rostock, Germany., Mannepalli S; Centogene GmbH, Am Strande 7, 18057, Rostock, Germany., Kandaswamy KK; Centogene GmbH, Am Strande 7, 18057, Rostock, Germany., Di Bucchianico S; Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany., Zimmermann R; Institute of Chemistry, University of Rostock, Dr.-Lorenz-Weg 2, 18059, Rostock, Germany.; Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany., Rolfs A; Centogene GmbH, Am Strande 7, 18057, Rostock, Germany.; Arcensus GmbH, Goethestrasse 20, 18055, Rostock, Germany., Bauer P; Centogene GmbH, Am Strande 7, 18057, Rostock, Germany.; Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine, University of Rostock, Rostock, Germany., Beetz C; Centogene GmbH, Am Strande 7, 18057, Rostock, Germany. christian.beetz@centogene.com.
Jazyk: angličtina
Zdroj: Orphanet journal of rare diseases [Orphanet J Rare Dis] 2022 May 03; Vol. 17 (1), pp. 179. Date of Electronic Publication: 2022 May 03.
DOI: 10.1186/s13023-022-02288-8
Abstrakt: Background: Ceroid lipofuscinoses neuronal 6 (CLN6) disease belongs to the neuronal ceroid lipofuscinoses (NCLs), complex and genetically heterogeneous disorders with wide geographical and phenotypic variation. The first clinical signs usually appear between 18 months and 8 years, but examples of later-onset have also been reported. Common manifestations include ataxia, seizures, vision impairment, and developmental regression. Because these are shared by other neurological diseases, identification of CLN6 genetic variants is imperative for early diagnosis.
Results: We present one of the largest cohorts to date of genetically diagnosed CLN6 patients screened at a single center. In total 97 subjects, originating from 20 countries were screened between 2010 and 2020. They comprised 86 late-infantile, eight juvenile, and three adult-onset cases (two patients with Kufs disease type A, and one with teenage progressive myoclonic epilepsy). The male to female ratio was 1.06: 1.00. The age at referral was between six months and 33 years. The time from disease onset to referral ranged from less than 1 month to 8.3 years. The clinical phenotype consisted of a combination of symptoms, as reported before. We characterized a total of 45 distinct variants defining 45 distinct genotypes. Twenty-four were novel variants, some with distinct geographic associations. Remarkably, c.257A > G (p.H86R) was present in five out of 23 unrelated Egyptian individuals but in no patients from other countries. The most common genotype was homozygosity for the c.794_796del in-frame deletion. It was present in about one-third of CLN6 patients (28 unrelated cases, and 2 familial cases), all with late-infantile onset. Variants with a high likelihood of causing loss of CLN6 function were found in 21% of cases and made up 33% of all distinct variants. Forty-four percent of variants were classified as pathogenic or likely pathogenic.
Conclusions: Our study significantly expands the number of published clinical cases and the mutational spectrum of disease-associated CLN6 variants, especially for the Middle Eastern and North African regions. We confirm previous observations regarding the most prevalent symptoms and recommend including CLN6 in the genetic diagnosis of patients presenting with early-onset abnormalities of the nervous system, musculoskeletal system, and eye.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje